185 related articles for article (PubMed ID: 32934876)
1. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
[TBL] [Abstract][Full Text] [Related]
4. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma.
Moein HR; Rutledge B; Beydoun R; Ehrinpreis MN
Cureus; 2021 Apr; 13(4):e14414. PubMed ID: 33987063
[TBL] [Abstract][Full Text] [Related]
6. Long-term immune-related adverse events after discontinuation of immunotherapy.
Horisberger K; Portenkirchner C; Rickenbacher A; Biedermann L; Gubler C; Turina M
Immunotherapy; 2021 Jun; 13(9):735-740. PubMed ID: 33882697
[TBL] [Abstract][Full Text] [Related]
7. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
8. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
11. Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.
Kim S; Lahu G; Vakilynejad M; Soldatos TG; Jackson DB; Lesko LJ; Trame MN
Clin Transl Sci; 2022 Jun; 15(6):1430-1438. PubMed ID: 35191192
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
Yanai S; Toya Y; Sugai T; Matsumoto T
Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
[TBL] [Abstract][Full Text] [Related]
13. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
[TBL] [Abstract][Full Text] [Related]
14. Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib.
Sweep MWD; Tjan MJH; Gorris MAJ; Bol KF; Westdorp H
Front Immunol; 2023; 14():1212432. PubMed ID: 37435072
[TBL] [Abstract][Full Text] [Related]
15. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.
Domblides C; Gross-Goupil M; Ravaud A; Poullenot F; Daste A
Immunotherapy; 2021 Jun; 13(9):741-744. PubMed ID: 33906378
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.
Soma K; Nishida T; Osugi N; Morimura O; Adachi S; Fujii Y; Sugimoto A; Mukai K; Nakamatsu D; Matsumoto K; Yamamoto M
Clin J Gastroenterol; 2022 Feb; 15(1):128-133. PubMed ID: 34716545
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.
Nassri AB; Muenyi V; AlKhasawneh A; Ribeiro BS; Scolapio JS; Malespin M; de Melo SW
World J Gastrointest Pharmacol Ther; 2019 Jan; 10(1):29-34. PubMed ID: 30697447
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-Induced Colitis in a Patient With Esophageal Adenocarcinoma: A Case Report.
Vlachos I; Karamanolis G; Vezakis A; Dellaportas D; Myoteri D
Cureus; 2023 Jul; 15(7):e42315. PubMed ID: 37614260
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
20. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
